GSK Advair Panel Review Will Focus On Single Survival Study
This article was originally published in The Pink Sheet Daily
Executive SummaryFDA is asking the Pulmonary-Allergy Drugs Advisory Committee whether results of GSK’s sole survival study are robust and what additional data would be needed for a survival claim.
You may also be interested in...
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.